Azienda Ospedaliero-universitaria Careggi

Protera S.r.l.

Università Degli Studi Di Firenze

Universitá Degli Studi Di Siena

Consorzio Interuniversitario Nazionale Per La Scienza E Tecnologia Dei Materiali

Dragoni, Elisa

Ghelardini, Carla

La Marca, Giancarlo

Consorzio Interuniversitario Nazionale Per La Scienza E La Tecnologia Dei Materiali (instm)

Nativi, Cristina

Cristina Nativi

Carla Ghelardini

Lucio Toma

Barbara Richichi

Carlotta Lunghi

Claudio Luchinat

Ivano Bertini

Marco Fragai

Giancarlo La Marca

Mauro Lo Conte

Chiara Venturi

Marco Consumi

Oscar Francesconi

Veronica Baldoneschi

Elisa Dragoni

Agnese Magnani

Gemma Leone

Stefania Lamponi

A specific antibody against a compound of formula (I) wherein X is O, NH, S, CH; L is a linker that is a divalent spacer; A is an adjuvant or carrier that is an immunogenic molecule or an immunogenic particle; and wherein bonds between linker and saccharide moiety and between linker and carrier are of covalent type; wherein the linker L presents a chemical structure suitable to space the saccharide moiety and the carrier by 7-30 atoms when the adjuvant/carrier A is a biomacromolecule or by 19-30 atoms when the adjuvant/carrier A is a metallic nanoparticle; wherein the carrier/adjuvant A can be selected among a macromolecule, a macrocycle, a dendrimer, a liposome, a nanoparticle, an oligosaccharide featuring from two to five monosaccharidic units or cells like dendritic cells.

Immunogenic synthetic glycoconjugate for the immunotherapy of melanoma

The present invention refers to compounds of formula (I) as useful melanoma vaccines' active ingredients. As a matter of fact, compounds of formula (1) are immunogenic artificial antigens, mimetics of GM3 and GM3 lactone, well known tumor associated antigens (TAAs). In addition, the present invention refers to specific antibodies for compounds of formula (I) which are able to bind to the TAAs. The hereinabove reported compounds and antibodies are therefore potentially useful respectively for the active and passive immunization against tumors over-expressing GM3 ganglioside, in a preferred embodiment melanoma and colon cancer, and for their diagnosis and prognosis.

Synthetic immunogenic glycoconjugate for melanoma immunotherapy

Described herein are derivatives of arylsulfonamido-substituted hydroxamic acid of formula (I) having good solubility in water and inhibitory activity of matrix metalloproteinases, useful for the preparation of pharmaceutical compositions for the treatment of diseases associated to a pathologic activity and/or an over-expression of metalloproteinases, and of cosmetic preparations having anti-ageing properties in particular for hair and skin. 

Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalloproteinases inhibitors

Growing community of inventors

Florence, Italy

Cristina Nativi